Trump Administration Launches $50 Medicare GLP-1 Program for 3 Weight-Loss Drugs
Updated
Updated · Scientific American · Jul 21
Trump Administration Launches $50 Medicare GLP-1 Program for 3 Weight-Loss Drugs
3 articles · Updated · Scientific American · Jul 21
Summary
$50-a-month pricing for Wegovy, Zepbound KwikPen and Foundayo began under the new Medicare GLP-1 Bridge program, aimed at expanding access for older adults with obesity.
38.9% of U.S. adults age 60 and older live with obesity, but experts say evidence for GLP-1 use in that group remains thin because older adults were underrepresented in trials.
40% of users can face side effects, and in seniors those risks can cascade into dehydration, falls, hypoglycemia and muscle loss that may undermine functional health.
18 months is the program's current duration, even though GLP-1s are typically long-term therapies and stopping them often leads to weight regain and possible worsening of underlying conditions.
1 in 10 Americans already takes a GLP-1, and clinicians say prescribing for seniors should focus on function and frailty rather than weight alone.